HLA-B*58:01 Typing

If you have gout, high uric acid, or a family history of either, there is one blood test worth knowing about before a doctor writes you a prescription for allopurinol. Allopurinol is one of the most commonly used drugs for gout worldwide, and for a small group of people, it can trigger a severe skin reaction called SCAR (severe cutaneous adverse reaction) that includes Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. These reactions can be fatal.

HLA-B*58:01 (a specific variant of the human leukocyte antigen B gene) is the single strongest genetic predictor of that reaction. It is a one-time test. Your result does not change over your lifetime, and knowing it before you ever start allopurinol changes what your doctor can safely prescribe.

What This Test Actually Measures

HLA-B is a gene that codes for a protein sitting on the surface of nearly every cell in your body. Its job is to display small fragments of proteins to your immune system so that infected or abnormal cells can be spotted and destroyed. There are thousands of variants of HLA-B in the human population, and HLA-B*58:01 is one specific version.

The test reads your DNA and reports whether you carry the HLA-B*58:01 variant. Results are binary: you are either positive (you carry at least one copy) or negative (you do not carry it). There is no middle ground and no number to track over time. Whether carrying two copies (homozygous) confers even higher risk than one copy is debated: some studies have reported a gene-dose effect, while other expert guidelines conclude there is no meaningful difference between heterozygous and homozygous carriers.

Why the Allopurinol Connection Matters

When allopurinol enters your body, it is converted into a metabolite called oxypurinol. In people who carry HLA-B58:01, allopurinol and oxypurinol appear to interact with the HLA-B58:01 molecule on immune cells. More recent research suggests two overlapping mechanisms: the drug can non-covalently promote binding of unusual peptide fragments to the HLA-B*58:01 groove, and oxypurinol can directly activate T cells through the receptor itself without needing normal antigen processing. Either way, cytotoxic T cells end up treating the resulting complex as a foreign threat, and the reaction that follows can destroy skin cells across the body.

The strength of the link is unusually large for a genetic risk marker. A 2025 meta-analysis pooling 24 case-control studies with 13,719 participants found that people carrying HLA-B*58:01 were about 117 times more likely to develop allopurinol-induced SCAR than non-carriers (odds ratio 117.6, 95% CI 70.3 to 196.8). In Han Chinese and Thai cohorts, the reported odds ratios climb into the hundreds.

Stevens-Johnson Syndrome, TEN, and DRESS

The reactions this variant predicts are not typical rashes. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) cause widespread skin blistering and shedding, often starting in the mouth and eyes, and can be life-threatening. DRESS (drug reaction with eosinophilia and systemic symptoms) presents as fever, rash, and multi-organ involvement, sometimes weeks after starting the drug.

In a Taiwan case series, the HLA-B58:01 allele was present in 100% of 51 patients with allopurinol-induced SCAR, versus about 15% of allopurinol-tolerant patients (20 of 135). In a Portuguese cohort, HLA-B58:01 was also identified as a significant risk factor for both DRESS and SJS/TEN, with carrier rates in cases substantially exceeding those seen in the general European population (roughly 2 to 4%). The pattern holds across ancestries, though the magnitude of the association varies.

Kidney Function and Compounded Risk

Risk is not driven by the gene alone. In one study, carriers with normal kidney function had an odds ratio of about 15 for allopurinol reactions, while carriers who were homozygous (two copies) and had severe kidney impairment had an odds ratio of 1,269. This is why kidney function testing usually goes hand in hand with HLA-B*58:01 typing when someone is being considered for urate-lowering therapy.

What this means for you: if you have chronic kidney disease and are being considered for allopurinol, checking this variant matters more than for someone with normal kidneys. The combination of kidney impairment and carrier status pushes risk into a range where alternative drugs are usually preferred.

Ancestry and Carrier Frequency

How often people carry HLA-B*58:01 varies substantially by ancestry. In the 2025 meta-analysis, pooled carrier prevalence in healthy populations was 5.8% overall, 12.9% in South and Southeast Asian populations, 7.7% across Asian populations broadly, and 2.3% in Eastern and Western European populations. Within Chinese subgroups, prevalence has ranged from about 2% in Uighur populations to 17% in Buyei populations.

In practical terms, testing has the highest expected benefit in people of Asian ancestry, especially Han Chinese, Korean, Thai, Vietnamese, and Filipino heritage. It is also increasingly emphasized for people of African American descent based on newer US data. Testing in people of European ancestry is less commonly done but still meaningful if you are considering allopurinol long term.

Reconciling a Counterintuitive US Finding

One 2025 US case-control study of 176 people (16 SCAR cases and 160 matched controls) found that while HLA-B58:01 was strongly associated with allopurinol-induced SCAR (odds ratio 28.0, 95% CI 8.6 to 100.6), the allele was still absent in more than one-third of the SCAR cases. In the same cohort, a second variant (HLA-A34:02) turned up as an independent risk factor (odds ratio 20.6). This does not contradict the strong link. It refines it. HLA-B*58:01 remains the single most important genetic predictor, but a negative result does not fully rule out risk, particularly in genetically heterogeneous populations. Think of it as a very strong signal that reduces risk substantially when negative, not a guarantee of safety.

Screening Prevents Reactions in the Real World

The prevention story is not theoretical. In a Taiwan national prospective cohort that enrolled 2,926 people needing allopurinol (with DNA analyzed from 2,910 after exclusions), carriers (about 20% of the cohort) were switched to alternative treatments. Zero SCAR cases developed among screen-negative patients started on allopurinol, versus about seven cases expected based on historical incidence. A separate Taiwan hospital analysis showed allopurinol-related SCAR dropped from 0.21% to 0% after HLA-B*58:01 testing was introduced. In Filipino patients in Hawaii, 7.2% tested positive; among 97 screen-negatives who then took allopurinol, no SCAR occurred.

The 2020 American College of Rheumatology guideline conditionally recommends HLA-B*58:01 testing before allopurinol in patients of Southeast Asian descent (e.g., Han Chinese, Korean, Thai) and African American patients, given their higher carrier rates. Real-world implementation shows that when testing happens before the first dose, severe reactions become rare.

One-Time Result, Lifetime Value

Because HLA-B*58:01 is a genetic variant, your result is set at birth and does not change. There is no reason to retest yourself once you have a validated result from a clinical-grade laboratory. The value comes from acting on it. Keep the result in your medical record and share it any time a clinician is considering starting you on allopurinol or a similar urate-lowering drug that goes through the same immune pathway.

If you carry the variant and have gout, that does not mean your uric acid goes unmanaged. It means alternatives should be considered, and current guidelines and the FDA label note that allopurinol may still be used in carriers if the benefits are judged to outweigh the risks after a careful discussion with your clinician. Ongoing monitoring should focus on serum uric acid, kidney function, and gout flares, not on repeating this genetic test.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects HLA-B*58:01 as designed. Rare related suballeles may be missed by narrow assays. If a result is ambiguous, high-resolution sequencing can resolve it.
• Allele dropout: certain intronic changes near the primer-binding sites of PCR-based assays can cause the test to fail to detect a copy of the gene, producing a false negative. This has been documented in published cases and is why clinical-grade laboratories use validated methods with multiplatform confirmation when calls are inconclusive.
• Ancestry-specific gaps: a negative result reduces your risk substantially but does not eliminate it, especially outside Asian populations. In one US cohort, more than a third of SCAR cases lacked the allele.
• Direct-to-consumer versus clinical: some consumer genetic services report HLA information at low resolution or through imputation, which is not reliable enough for a prescribing decision. Use a clinical-grade pharmacogenetic assay if the result will drive drug choice.

What to Do With an Out-of-Pattern Result

If you test positive, discuss alternatives with your clinician before starting or continuing allopurinol. Guidelines and the FDA label allow allopurinol to still be considered in carriers when the benefits are judged to outweigh the risks, but for most people alternative urate-lowering drugs are preferred because your risk of a severe reaction is substantially higher than average. Share the result with first-degree relatives (parents, siblings, children), because each has a meaningful chance of also carrying the variant and could benefit from knowing before they need urate-lowering therapy themselves.

If you test negative but have a personal or family history of severe drug reactions, mention this to your clinician. Additional risk factors, including HLA-A34:02 and kidney impairment, can still elevate risk, and a broader pharmacogenetic workup may be appropriate before starting allopurinol. Companion tests worth considering alongside HLA-B58:01 include serum uric acid, kidney function (creatinine, cystatin C, eGFR), and, in select populations, expanded HLA typing.